IRCT2016041920441N4已完成未知
Omega-3 in the prevention of contrast-induced nephropathy after percutaneous coronary intervention
Shiraz University of Medical Sciences, international branch0 个研究点目标入组 80 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 80 years（—）
- 性别
- All
入选标准
- •Inclusion criteria included GFR more than 60 ml/min/1.73 m2; the ages of 18 to 80 years; patients undergoing elective PCI. Exclusion criteria: Pretreatment with N-acetyl cystein or intravenous vitamin C; sensitivity or tolerance to ASA or Clopidogrel or omega-3; sever adverse effects to drugs
排除标准
- 未提供
研究者
相似试验
已完成
不适用
The role of Omega-3 polyunsaturated fatty acids in the prevention of contrast-induced nephropathy (CIN) after percutaneous coronary intervention (PCI) in chronic kidney disease (CKD) patientsrenal disease.Nephropathy induced by other drugs, medicaments and biological substancesIRCT2016031320441N3Vice chancellor for research, Shiraz University of Medical Sciences, International branch80
已完成
不适用
Effect of omega 3 in the prevention of 30-days major adverse cardiovascular events following Carotid StentingIRCT2017011120441N6Shiraz University of Medical Sciences, Vice Chancellor of Research60
招募中
不适用
Survey of the Effect of Omega-3 in the Prevention of Preeclampsia”IRCT20210426051094N1Kurdistan University of Medical Sciences72
尚未招募
不适用
Omega-3 fish oil for the prevention of Gestational DiabetesGestational DiabetesACTRN12617000177358The University of Newcastle74
进行中（未招募）
不适用
Omega-3 fatty acids for Prevention of post-opERative Atrial fibrillation (OPERA) - OPERAPatients scheduled for cardiac surgeryMedDRA version: 9.1Level: SOCClassification code 10007541EUCTR2009-017582-29-ITCONSORZIO MARIO NEGRI SUD1,516